The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, Niels Ejskjaer*

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

15 Citations (Scopus)
65 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science